目錄[21]中提到對(duì)于降壓藥物的選擇上采用的原則為血壓小于160/100mmHg的采用單一藥物治療，在2-4周治療后未達(dá)標(biāo)就兩種藥物聯(lián)合。兩種藥物聯(lián)合一般采納ACEI或ARB類(lèi)藥物加上CCB類(lèi)藥物，如纈沙坦膠囊聯(lián)合苯磺酸氨氯地平片；利尿劑加上ACEI或ARB類(lèi)藥物，如纈沙坦膠囊聯(lián)合螺內(nèi)酯片；CCB類(lèi)藥物加上利尿劑，如呋塞米片聯(lián)合苯磺酸氨氯地平片；β受體阻滯劑加上CCB類(lèi)藥物，如琥珀酸美托洛爾緩釋片聯(lián)合苯磺酸氨氯地平片。如2-4周仍未達(dá)到標(biāo)準(zhǔn)閾值，則進(jìn)行三種藥物聯(lián)合ACEI和ARB與CCB類(lèi)藥物與β受體阻滯劑聯(lián)合或合ACEI和ARB與CCB類(lèi)藥物與利尿劑聯(lián)合。參考文獻(xiàn)參考文獻(xiàn)[SEQ文獻(xiàn)\*ARABIC1]RobertsJM,LindheimerM,PearsonG,etal.SummaryoftheNHLBIWorkingGrouponResearchon.[J].Hypertension:AnOfficialJournaloftheAmericanHeartAssociation,2003,41(3):437-445.[SEQ文獻(xiàn)\*ARABIC2]TsengYuan-Fu,LinHsiu-Chen,ChaoJaneChen-Jui,etal.CalciumChannelblockersareassociatedwithreducedriskofParkinson'sdiseaseinpatientswithhypertension:Apopulation-basedretrospectivecohortstudy[J].JournaloftheNeurologicalSciences,2021,424[SEQ文獻(xiàn)\*ARABIC3]ContaldiElena,MagistrelliLuca,MilnerAnna,etal.PotentialprotectiveroleofACE-inhibitorsandAT1receptorblockersagainstlevodopa-induceddyskinesias:aretrospectivecase-controlstudy[J].NeuralRegenerationResearch,2021,16(12):2475-2478.[SEQ文獻(xiàn)\*ARABIC4]LiuRuru,MiBaibing,ZhaoYaling,etal.Gender-specificassociationbetweencarbohydrateconsumptionandbloodpressureinChineseadults[J].BMJNutrition,Prevention&Health,2021[SEQ文獻(xiàn)\*ARABIC5]NaryzhnayaNatalia,KurbatovBoris,GorbunovAlexander,etal.Highcarbohydratehighfatdietinducestheproductionofconnectivetissuegrowthfactors,increasedbloodpressure,andchangesintheaorticwallinagedrats[J].TheFASEBJournal,2021,35[SEQ文獻(xiàn)\*ARABIC6]YankeyBarbaraA,RothenbergRichard,StrasserSheryl,etal.Effectofmarijuanauseoncardiovascularandcerebrovascularmortality:AstudyusingtheNationalHealthandNutritionExaminationSurveylinkedmortalityfile[J].EuropeanJournalofPreventiveCardiology,2017,24(17):1833-1840.DOI:10.1177/2047487317723212.[SEQ文獻(xiàn)\*ARABIC7]KaraSonatP?nar,OzkanGulsum,Y?lmazAhsen,etal.MicroRNA21andmicroRNA155levelsinresistanthypertension,andtheirrelationshipswithaldosterone.[J].RenalFailure,2021,43(1):676-683.[SEQ文獻(xiàn)\*ARABIC8]何玉雯.兩種劑量苯磺酸氨氯地平治療高血壓的臨床效果比較[J].臨床合理用藥雜志,2019,12(13):53-54.DOI:10.15887/ki.13-1389/r.2019.13.027.[SEQ文獻(xiàn)\*ARABIC9]何文文,何美青.苯磺酸氨氯地平和苯磺酸左旋氨氯地平治療高血壓的效果對(duì)比[J].中國(guó)生化藥物雜志,2017,37(8):193-194.DOI:10.3969/j.issn.1005-1678.2017.08.079.[SEQ文獻(xiàn)\*ARABIC10]王士強(qiáng),唐楊章,張懷金等.硝苯地平控釋片治療老年單純性收縮期高血壓的臨床研究[J].中國(guó)臨床藥理學(xué)雜志,2017,33(14):1298-1300.DOI:10.13699/ki.1001-6821.2017.14.003.[SEQ文獻(xiàn)\*ARABIC11]周欣滿(mǎn).纈沙坦治療輕中度高血壓療效及安全性評(píng)價(jià)[J].中國(guó)藥業(yè),2016,25(23):50-52,53.[SEQ文獻(xiàn)\*ARABIC12]王國(guó)鋒,韓碩,王琦等.琥珀酸美托洛爾緩釋片治療原發(fā)性高血壓臨床療效觀(guān)察[J].中國(guó)血液流變學(xué)雜志,2020,30(1):50-52.DOI:10.3969/j.issn.1009-881X.2020.01.010.[SEQ文獻(xiàn)\*ARABIC13]鄭世路,王春雷,遲玉霞等.美托洛爾治療高血壓的用藥劑量分析[J].醫(yī)學(xué)信息（下旬刊）,2013,26(12):637.[SEQ文獻(xiàn)\*ARABIC14]殷莉.小劑量β-受體阻滯劑治療老年性高血壓導(dǎo)致嚴(yán)重心動(dòng)過(guò)緩[J].重慶醫(yī)學(xué),2004,33(2):268-269.DOI:10.3969/j.issn.1671-8348.2004.02.052.[SEQ文獻(xiàn)\*ARABIC15]王杜娟.纈沙坦聯(lián)合酒石酸美托洛爾治療老年高血壓的臨床探究[J].當(dāng)代醫(yī)學(xué),2017,23(12):101-103.DOI:10.3969/j.issn.1009-4393.2017.12.050.[SEQ文獻(xiàn)\*ARABIC16]朱春燕.苯磺酸氨氯地平(絡(luò)活喜)與纈沙坦(代文)聯(lián)合治療高血壓的療效分析[J].健康必讀,2019,(6):93-94.[SEQ文獻(xiàn)\*ARABIC17]張進(jìn)美.苯磺酸氨氯地平聯(lián)合酒石酸美托洛爾治療頑固性高血壓的臨床療效[J].中外女性健康研究,2020,(21):53-54.[SEQ文獻(xiàn)\*ARABIC18]管紅斌,何凱平,桓文穆等.螺內(nèi)酯聯(lián)合纈沙坦對(duì)高血壓早期腎損害患者尿微量白蛋白及腎功能的影響[J].國(guó)際醫(yī)藥衛(wèi)生報(bào),2019,25(9):1420-1423.DOI:10.3760/cma.j.issn.1007-1245.2019.09.019.[SEQ文獻(xiàn)\*ARABIC19]林永陽(yáng).高血壓患者聯(lián)合用藥的合理性與不良反應(yīng)特點(diǎn)及聯(lián)合用藥禁忌證[J].臨床合理用藥雜志,2018,11(18):105-106.DOI:10.15887/ki.13-1389/r.2018.18.051.[SEQ文獻(xiàn)\*ARABIC20]楊華.高血壓患者聯(lián)合用藥的禁忌[J].中西醫(yī)結(jié)合